Shuttle Pharma Secures $4.25 Million in Private Placement Deal
Biotech firm taps accredited investor to support acquisitions and marketing efforts.
Shuttle Pharmaceuticals (NASDAQ: SHPH) has locked in a $4.25 million private placement with an accredited investor, bolstering its war chest as the company continues to develop therapies that enhance the effectiveness of radiation therapy (RT) for cancer patients. The offering, priced at-the-market under Nasdaq rules, involves the sale of 1,180,877 shares of common stock, or pre-funded warrants, at $3.60 per share.
The transaction, announced on June 20, 2025, positions the development-stage biotech company to advance its strategic goals, which include potential acquisitions, expanded marketing initiatives, and broader corporate objectives. Shuttle Pharma confirmed that WestPark Capital will serve as the exclusive placement agent for the offering, which is expected to close on or around June 23, pending customary closing conditions.
Fueling Growth and Expanding Reach
With the additional capital, Shuttle Pharmaceuticals aims to ramp up efforts to strengthen its position in the oncology space. The company remains focused on improving outcomes for cancer patients undergoing radiation therapy by developing radiation sensitizers, compounds that enhance the ability of radiation to destroy cancer cells while minimizing damage to healthy tissue.
According to the company, the funds will support its broader mission to improve survival rates and quality of life for cancer patients. This infusion of capital could also signal future business development activity, particularly acquisitions that align with Shuttle’s growth strategy.
Regulatory Framework and Offering Mechanics
The securities included in the private placement have not been registered under the Securities Act of 1933 and will only be offered to accredited investors. As part of the deal, Shuttle agreed to a registration rights agreement, committing to file one or more registration statements with the Securities and Exchange Commission (SEC) to cover the resale of both the shares and any shares issued through the exercise of pre-funded warrants.
The company noted it will disclose further information regarding the transaction in a forthcoming Form 8-K filing with the SEC.
Positioned for Impact in Cancer Therapy
Shuttle Pharmaceuticals continues to push forward as a specialty biotech firm focused squarely on the intersection of radiation therapy and pharmaceutical innovation. By working to improve the therapeutic index of RT, the company hopes to boost cancer cure rates, extend survival, and reduce the collateral damage of treatment.
With this latest funding round, SHPH has taken a meaningful step toward executing that vision. Investors will now watch closely to see how the company deploys its new capital in a sector where innovation could mean the difference between remission and recurrence.
Read Next: This Biotech Stock Took The Center Stage at the Planet MicroCap Showcase: VEGAS 2025
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
